- Home
- GOSS vs PPT Comparison
GOSS vs PPT Comparison
Compare GOSS & PPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- PPT
- Stock Information
- Founded
- GOSS 2015
- PPT 1988
- Country
- GOSS United States
- PPT United States
- Employees
- GOSS N/A
- PPT N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- PPT Finance Companies
- Sector
- GOSS Health Care
- PPT Finance
- Exchange
- GOSS Nasdaq
- PPT Nasdaq
- Market Cap
- GOSS 347.8M
- PPT 356.5M
- IPO Year
- GOSS 2019
- PPT N/A
- Fundamental
- Price
- GOSS $2.47
- PPT $3.70
- Analyst Decision
- GOSS Strong Buy
- PPT
- Analyst Count
- GOSS 4
- PPT 0
- Target Price
- GOSS $8.50
- PPT N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- PPT 156.1K
- Earning Date
- GOSS 08-05-2025
- PPT 01-01-0001
- Dividend Yield
- GOSS N/A
- PPT 8.84%
- EPS Growth
- GOSS N/A
- PPT N/A
- EPS
- GOSS N/A
- PPT N/A
- Revenue
- GOSS $40,237,000.00
- PPT N/A
- Revenue This Year
- GOSS N/A
- PPT N/A
- Revenue Next Year
- GOSS $30.65
- PPT N/A
- P/E Ratio
- GOSS N/A
- PPT N/A
- Revenue Growth
- GOSS N/A
- PPT N/A
- 52 Week Low
- GOSS $0.66
- PPT $3.25
- 52 Week High
- GOSS $2.65
- PPT $3.72
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- PPT 54.54
- Support Level
- GOSS $2.38
- PPT $3.64
- Resistance Level
- GOSS $2.65
- PPT $3.73
- Average True Range (ATR)
- GOSS 0.15
- PPT 0.03
- MACD
- GOSS 0.03
- PPT 0.00
- Stochastic Oscillator
- GOSS 76.67
- PPT 61.11
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About PPT Putnam Premier Income Trust
Putnam Premier Income Trust is a Massachusetts business trust operating as a non-diversified closed-end management investment company. The fund is currently operating as a diversified fund. Its investment objective is to seek high current income consistent with the preservation of capital by allocating its investments to the U.S. government sector.